[[1]](#footnote-10620)



**December 31, 2024**

**High-Cost Specialty Drug (BIO) Amtagvi has been removed from AHCCCS Covered Services**

The High-Cost Specialty Drug, Amtagvi (lifileucel), is excluded from coverage under the AHCCCS Program. All products from the manufacturer, Iovance Biotherapeutics Manufacturing, have been excluded from coverage because the manufacturer has not complied with CMS regulations and signed the CMS Federal Rebate Agreement. In addition, Amtagvi, which is manufactured by Iovance, is not eligible for MCO reimbursement under the AHCCCS Reinsurance Program.

1. [↑](#footnote-ref-10620)